Caris Life Sciences, Inc. is 1.1x more valuable than BillionToOne, Inc. by market capitalization ($4.85 B vs $4.51 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BLLN | CAI |
|---|---|---|
| Market cap | $4.51 B | $4.85 B |
| US-listed rank | #1479 | #1404 |
| Revenue (latest FY) | $305.11M | $812.03M |
| Net income (latest FY) | $7.45M | -$68.09M |
| Net margin | 2.4% | -8.4% |
| P/E (trailing FY) | 605.0 | - |
| SEC filings | 61 | 102 |
Caris Life Sciences, Inc. is 1.1x more valuable than BillionToOne, Inc. by market capitalization ($4.85 B vs $4.51 B).
In their latest fiscal years, BillionToOne, Inc. reported $305.11M in revenue while Caris Life Sciences, Inc. reported $812.03M.
Full pages: BillionToOne, Inc. and Caris Life Sciences, Inc., or browse the full rankings.